ACSL5, a prognostic factor in acute myeloid leukemia, modulates the activity of Wnt/β-catenin signaling by palmitoylation modification.
10.1007/s11684-022-0942-1
- Author:
Wenle YE
1
;
Jinghan WANG
1
;
Jiansong HUANG
1
;
Xiao HE
2
;
Zhixin MA
3
;
Xia LI
1
;
Xin HUANG
1
;
Fenglin LI
1
;
Shujuan HUANG
1
;
Jiajia PAN
1
;
Jingrui JIN
1
;
Qing LING
1
;
Yungui WANG
1
;
Yongping YU
4
;
Jie SUN
5
;
Jie JIN
6
Author Information
1. Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, 310003, China.
2. Research Centre, Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, H2L 4M1, Canada.
3. Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, 310006, China.
4. Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
5. Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, 310003, China. sunjiehm@zju.edu.cn.
6. Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, 310003, China. jiej0503@zju.edu.cn.
- Publication Type:Journal Article
- Keywords:
ABT-199;
Wnt3a;
acute myeloid leukemia;
acyl-CoA synthetase long chain family member 5;
palmitoylation
- MeSH:
Humans;
Antineoplastic Agents/therapeutic use*;
Apoptosis;
beta Catenin/metabolism*;
Biomarkers, Tumor/metabolism*;
Cell Line, Tumor;
Coenzyme A Ligases/metabolism*;
Leukemia, Myeloid, Acute/metabolism*;
Lipoylation;
Prognosis;
Wnt Signaling Pathway
- From:
Frontiers of Medicine
2023;17(4):685-698
- CountryChina
- Language:English
-
Abstract:
Acyl-CoA synthetase long chain family member 5 (ACSL5), is a member of the acyl-CoA synthetases (ACSs) family that activates long chain fatty acids by catalyzing the synthesis of fatty acyl-CoAs. The dysregulation of ACSL5 has been reported in some cancers, such as glioma and colon cancers. However, little is known about the role of ACSL5 in acute myeloid leukemia (AML). We found that the expression of ACSL5 was higher in bone marrow cells from AML patients compared with that from healthy donors. ACSL5 level could serve as an independent prognostic predictor of the overall survival of AML patients. In AML cells, the ACSL5 knockdown inhibited cell growth both in vitro and in vivo. Mechanistically, the knockdown of ACSL5 suppressed the activation of the Wnt/β-catenin pathway by suppressing the palmitoylation modification of Wnt3a. Additionally, triacsin c, a pan-ACS family inhibitor, inhibited cell growth and robustly induced cell apoptosis when combined with ABT-199, the FDA approved BCL-2 inhibitor for AML therapy. Our results indicate that ACSL5 is a potential prognosis marker for AML and a promising pharmacological target for the treatment of molecularly stratified AML.
